TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01359189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProxiScan (scintigraphic rectal probe)
Description: ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used.
Study: NCT04228601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: PARP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluzoparib placebo
Description: Placebo
Study: NCT02801942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Description: Blood sample (30 mL) will be collected, to derive immune cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Description: Blood sample (30 mL) will be collected, to derive immune cells.
Study: NCT03842228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT02801942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre- and post-biopsy questionnaire
Description: All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre- and post-biopsy questionnaire
Description: All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
Study: NCT00218296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Nicotine replacement therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction Group
Description: Subject selects preferred method for reduction.
Study: NCT01094496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1307 Vaccine Regimen
Description: CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study: NCT02717988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo 180 mg capsule filled with microcrystalline cellulose
Study: NCT02212587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOBI
Description: New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
Study: NCT03395158

Intervention type: DIAGNOSTIC_TEST
Intervention: Implementation of new alert criteria
Description: The intervention is when the prior alert criteria are replaced by the present alert criteria

Intervention type: DIAGNOSTIC_TEST
Intervention: Implementation of new alert criteria
Description: The intervention is when the prior alert criteria are replaced by the present alert criteria
Study: NCT01415063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE-RFA
Description: TACE first, then RFA within 2 weeks
Study: NCT04344314

Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral Intravenous Catheter
Description: Randomised controlled
Study: NCT04228601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX
Study: NCT01071317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: 100mg po q day prn headache

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Migraine education
Description: Educational program available through NIH/ national library of medicine/ X-plain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reenforcement of diagnosis
Description: Patient advised has migraine headache and how the headache meets migraine criteria

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical care
Description: Care to be determined by attending physician
Study: NCT03899909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SAD
Description: Placebo oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121 MAD
Description: GLPG3121 oral suspension, multiple ascending doses, daily for 13 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MAD
Description: Placebo oral suspension, daily for 13 days
Study: NCT04228601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX
Study: NCT02263443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soap suds enema (S.S.E.)
Description: Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sodium chloride enema
Description: Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No enema
Description: Patients NPO groups will NPO and no bowel preparation.
Study: NCT01836328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral /oral methadone ratio 1:2
Description: See arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral /oral methadone ratio 1:1.2
Description: See arm/group descriptions
Study: NCT03287037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS over DLPFC
Description: We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
Study: NCT01635803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab administered by monthly interval for six months (6 injections).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5mg ranibizumab administered by monthly interval for six months (6 injections).
Study: NCT03964688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: vitamin C intravenous during hospitalization, after oral, total 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo intravenous during hospitalization, after oral, total 6 weeks
Study: NCT00386165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: larazotide acetate 4 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: larazotide acetate
Description: larazotide acetate 4 mg capsules
Study: NCT02396368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
Study: NCT01906710

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated medicines management
Description: PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge
Study: NCT04911283

Intervention type: OTHER
Intervention: Brucella serology test
Description: MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.

Intervention type: OTHER
Intervention: Brucella serology test
Description: MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.

Intervention type: OTHER
Intervention: Medical history for brucellosis
Description: Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.

Intervention type: OTHER
Intervention: Medical history for brucellosis
Description: Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.

Intervention type: OTHER
Intervention: Medical history for brucellosis
Description: Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
Study: NCT00324467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
Study: NCT01666665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
Study: NCT01516944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin
Description: Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin
Description: Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin; Capecitabine
Description: Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
Study: NCT01666665

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill up to 3 times per day for 12 months
Study: NCT01699958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention
Description: Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
Study: NCT04653025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: After tooth extraction implants were placed either immediate or delayed approach

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: After tooth extraction implants were placed either immediate or delayed approach
Study: NCT01228799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Description: trabeculectomy with mitomycin C 0.2mg/ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canaloplasty
Description: Canaloplasty with implant of suture
Study: NCT01659125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCFighter
Description: OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
Study: NCT03066258

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
Study: NCT01480245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968
Description: 6mg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968
Description: 6mg/kg/week
Study: NCT00621270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-540
Description: BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCI-540
Description: BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCI-540
Description: BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
Study: NCT00367302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: maintenance
Study: NCT03172195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectosigmoidoscopy
Description: A rectosigmoidoscopy will be realized and two fragments will be collected.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biopsies
Description: For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Blood sample will be collected in more.
Study: NCT03578393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Educational Program
Description: The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
Study: NCT02396368

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium 223
Description: Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
Study: NCT01151397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg + Vitamin D + Ribavirin
Description: Peg+ Vitamin D+ Ribavirin for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg + Ribavirin
Description: Peg+ Ribavirin for 6 months
Study: NCT01701115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block
Description: Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL
Study: NCT00919815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: prednisolone 40mg daily then reducing regimen over 24 weeks
Study: NCT03369483

Intervention type: OTHER
Intervention: Abdominal pressure assessment
Description: We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
Study: NCT01914692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
Study: NCT01192412

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention is blood pressure management approach
Description: 1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is \>105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP \<100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention is blood pressure management approach.
Description: 'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is \<80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is \>85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.